• Coventry University Featured PhD Programmes
  • Lancaster University Featured PhD Programmes
  • FindA University Ltd Featured PhD Programmes
  • University of Manchester Featured PhD Programmes
  • University of Glasgow Featured PhD Programmes
  • University of Birmingham Featured PhD Programmes
  • Ross University School of Veterinary Medicine Featured PhD Programmes
Ludwig-Maximilians-Universität Munich Featured PhD Programmes
FindA University Ltd Featured PhD Programmes
Coventry University Featured PhD Programmes
Imperial College London Featured PhD Programmes
University of Reading Featured PhD Programmes

Suppression of p53 by Metastasis-Associated MAGE-A Proteins in melanoma

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr D W Meek
  • Application Deadline
    Applications accepted all year round

Project Description

MAGE-A (melanoma antigen) proteins comprise a 12-member sub-family of cancer/testis (CT) antigens, so called because, physiologically, they are expressed almost exclusively in the testis, but during the development of a range of cancers (including melanoma where they were initially discovered) their expression is re-activated and is tightly associated with malignancy (i.e. with invasion and metastasis). Experimental evidence supports the idea that they are actually drivers of the malignant phenotype. We, and others, have established that several MAGE-A proteins are potent direct inhibitors of the p53 tumour suppressor and stimulate the levels of the crucial p53 inhibitor, MDM4.

We hypothesise that expression of MAGE-A proteins suppresses p53 tumour suppressor function during the development of melanoma, a form of cancer that generally retains wild type p53 status but frequently expresses high levels of MAGE-A proteins and MDM4. To explore this idea the project will identify amino acids in MAGE-A2 (as a representative member of the MAGE-A family) that are required to make contact with p53 and/or other key regulators of the p53 network. A series of MAGE-A2 mutants will be tested for their ability to associate with p53 in vitro (pulldown assays) and in cultured cells (co-immunoprecipitation assays). They shall also be tested functionally to determine whether they can mediate inhibition of p53 function/signalling, regulate MDM4 levels, and to block p53-mediated apoptosis. Based on these analyses, further fine-tuning analysis will be conducted by generating and testing appropriate point mutations. These analyses will be an integral component of ongoing studies aimed at establishing the mechanism of p53 inhibition by MAGE-A and identifying interacting regions/domains that can be explored as potential therapeutic targets.


[1] L. Marcar, N.J. Maclaine, T.R. Hupp, and D.W. Meek, Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 70 (2010) 10362-10370.
[2] D.W. Meek, and L. Marcar, MAGE-A antigens as targets in tumour therapy. Cancer Lett (2012) 324, 126-132.
[3] A.J. Simpson, O.L. Caballero, A. Jungbluth, Y.T. Chen, and L.J. Old, Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5 (2005) 615-25.

How good is research at University of Dundee in Clinical Medicine?

FTE Category A staff submitted: 49.50

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities

Cookie Policy    X